Trials / Completed
CompletedNCT00161889
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 615 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three treatment groups of Baxter study 205 (safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Timeline
- Start date
- 2002-02-01
- Completion
- 2002-08-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
19 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00161889. Inclusion in this directory is not an endorsement.